Diamyd Medical
17.44 SEK -3.22%1 investor is following this company
Diamyd Medical is a diabetes company. The company develops the diabetes vaccine Diamyd® with the active ingredient GAD, which has the potential to become a key piece of the puzzle of a future solution to prevent, treat or cure type 1 diabetes and other forms of diabetes. Diamyd Medical has independently pursued the development of the diabetes vaccine Diamyd® to global Phase III trial.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
DMYD B
Daily low / high price
17.38 / 18.1
SEK
Market cap
1.74B SEK
Turnover
4.92M SEK
Volume
278K
Latest videos
Financial calendar
Annual report
09.10.2024
General meeting
05.12.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Avanza Pension | 12.9 % | 10.3 % |
Bertil Lindkvist | 9.2 % | 7.3 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Diamyd Medical AB: Diamyd Medical receives second U.S. FDA Fast Track designation for Diamyd® - for the prevention of Type 1 Diabetes
Diamyd Medical AB: Quarterly Report III 23/24
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools